Haichuan X. Su

NO. 569 Xinsi Road, 
Xi'an, CN 
Clinical Trials:Currently Recruiting for 1 Trial
NO. 569 Xinsi Road, 
Xi'an, CN 

Overview

Haichuan Su practices practicing medicine in Xi'an, China.

Their clinical expertise encompasses Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Small Cell Lung Cancer (SCLC), and Lung Cancer.

They are actively involved in clinical research, co-authoring 52 peer reviewed articles and participating in 3 clinical trials.

Locations

NO. 569 Xinsi Road, Xi'an, 710038, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
Enrollment Status: Recruiting
Publish Date: April 03, 2026
Intervention Type: Drug
Study Drug: Repotrectinib
Study Phase: Phase 1/Phase 2
A Open-label, Multicenter Phase II Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With HR-positive, HER2-negative Advanced Breast Cancer
A Open-label, Multicenter Phase II Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With HR-positive, HER2-negative Advanced Breast Cancer
Enrollment Status: Completed
Publish Date: April 08, 2026
Intervention Type: Drug
Study Drugs: TQB3616 Capsules, Fulvestrant Injection
Study Phase: Phase 2
View 1 Less Clinical Trial

52 Total Publications

Efficacy and safety of savolitinib in Chinese patients with locally advanced or metastatic MET exon 14-mutated non-small cell lung cancer: final results of a confirmatory Phase 3b study.
Efficacy and safety of savolitinib in Chinese patients with locally advanced or metastatic MET exon 14-mutated non-small cell lung cancer: final results of a confirmatory Phase 3b study.
Journal: The Lancet regional health. Western Pacific
Published: October 30, 2025

Frequently Asked Questions about Haichuan X. Su

Is Haichuan X. Su a top-rated expert for Pancreatic Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Haichuan X. Su is classified as an Experienced expert for Pancreatic Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Haichuan X. Su participate in research or clinical trials?

Yes. Haichuan X. Su has published 52 articles and abstracts on conditions like Pancreatic Cancer. You can view a list of Haichuan X. Su's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Su's expertise for a condition
ConditionClose
        View All 12 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile